Immucell (ICCC) Operating Income (2010 - 2026)
Immucell's (ICCC) quarterly Operating Income came in at -$57956.0 in Q4 2025, down 109.33% YoY from $621395.0 in Q4 2024, and down 388.7% on a QoQ basis from $20075.0 in Q3 2025.
Immucell (ICCC) Operating Income (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Operating Income data on file, last reported at -$57956.0 in Q4 2025.
- Quarterly Operating Income fell 109.33% year-over-year to -$57956.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (up 200.56% YoY) and the FY2025 annual result came in at $1.6 million, up 200.56% from the prior year.
- Operating Income fell to -$57956.0 in Q4 2025, from $20075.0 in the prior quarter.
- In the past five years, Operating Income ranged from a high of $1.1 million in Q1 2025 to a low of -$2.3 million in Q1 2023.
- A 5-year average of -$356683.7 and a median of -$300052.0 in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income plunged 1223.53% — and 2025, when it surged 472.48%.
- Tracing ICCC's Operating Income over 5 years: stood at $145412.0 in 2021, then sank by 1223.53% to -$1.6 million in 2022, then climbed by 27.53% to -$1.2 million in 2023, then jumped by 152.48% to $621395.0 in 2024, then plunged by 109.33% to -$57956.0 in 2025.
- The last three Operating Income figures came in at -$57956.0 (Q4 2025), $20075.0 (Q3 2025), and $569562.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn | 1.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.93 Mn |
| Dec 31, 2025 | -57,956.00 |
| Sep 30, 2025 | 20,075.00 |
| Jun 30, 2025 | 569,562.00 |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 621,395.00 |
| Sep 30, 2024 | -574,894.00 |
| Jun 30, 2024 | -1.39 Mn |
| Mar 31, 2024 | -300,052.00 |
| Sep 30, 2023 | -1.18 Mn |
| Jun 30, 2023 | -1.30 Mn |
| Mar 31, 2023 | -2.26 Mn |
| Dec 31, 2022 | -1.63 Mn |
| Sep 30, 2022 | -616,790.00 |
| Jun 30, 2022 | -619,007.00 |
| Mar 31, 2022 | 570,609.00 |
| Dec 31, 2021 | 145,412.00 |
| Sep 30, 2021 | 271,090.00 |
| Jun 30, 2021 | 215,508.00 |
| Mar 31, 2021 | -374,625.00 |